Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.48 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 5/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909423 | 0.85 | CCR1 (0.50) | CHRM2CHRM1CHRM3CCR1CXCR3 | |
| SCHEMBL5555057 | 0.81 | CCR1 (0.60) | CHRM2CHRM1CHRM3CCR1 | |
| SCHEMBL14760990 | 0.80 | DRD2 (0.51) | CHRM2CHRM1CHRM3CX3CR1EPHX2 | |
| SCHEMBL2772737 | 0.78 | EPHX2 (0.51) | CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL3487314 | 0.77 | CCR1 (0.44) | CHRM2CHRM1CHRM3CCR1CYP3A4 | |
| SCHEMBL1868922 | 0.76 | EPHX2 (0.49) | CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL15130431 | 0.76 | CHRM5 (0.48) | CHRM2CHRM1CHRM3CCR1 | |
| SCHEMBL15191011 | 0.76 | CHRM5 (0.48) | CHRM2CHRM1CHRM3CCR1 | |
| SCHEMBL27955416 | 0.75 | CHRM2 (0.37) | CHRM2CHRM1CHRM3CX3CR1EPHX2 | |
| SCHEMBL4119272 | 0.74 | CHRM5 (0.52) | CHRM2CHRM1CHRM3CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757103-B1 | PYRROLIDINE-3-YLACETIC ACID DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-8476301-B2 | Pyrrolidin-3-ylacetic acid derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20130065925-A1 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065925-A1 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE | CX3CR1, CCR2, CCL2 | CHRM2 164/4885CHRM1 187/4885CHRM3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.